Vigil Neuroscience (NASDAQ:VIGL) Downgraded by William Blair to Hold

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) was downgraded by investment analysts at William Blair from a "strong-buy" rating to a "hold" rating in a research report issued on Thursday, MarketBeat Ratings reports. William Blair also issued estimates for Vigil Neuroscience's FY2027 earnings at ($1.78) EPS.

VIGL has been the subject of a number of other reports. Wedbush reaffirmed an "outperform" rating and issued a $13.00 target price on shares of Vigil Neuroscience in a report on Monday, May 5th. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, HC Wainwright dropped their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, March 14th. Nine research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $11.50.

Vigil Neuroscience Trading Down 0.1%

Shares of VIGL traded down $0.01 during mid-day trading on Thursday, hitting $7.89. 1,668,133 shares of the company's stock were exchanged, compared to its average volume of 641,017. Vigil Neuroscience has a fifty-two week low of $1.31 and a fifty-two week high of $7.95. The firm has a market capitalization of $368.01 million, a P/E ratio of -3.83 and a beta of 1.90. The business's 50 day moving average is $2.31 and its two-hundred day moving average is $2.31.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, equities research analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Investors Weigh In On Vigil Neuroscience

Several hedge funds have recently made changes to their positions in the business. BVF Inc. IL boosted its holdings in shares of Vigil Neuroscience by 121.3% during the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock worth $7,144,000 after purchasing an additional 2,200,000 shares during the last quarter. 683 Capital Management LLC boosted its holdings in shares of Vigil Neuroscience by 24.3% during the first quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock worth $3,097,000 after purchasing an additional 340,000 shares during the last quarter. Aberdeen Group plc boosted its holdings in shares of Vigil Neuroscience by 226.3% during the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock worth $3,070,000 after purchasing an additional 1,196,048 shares during the last quarter. Blair William & Co. IL boosted its holdings in shares of Vigil Neuroscience by 219.1% during the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock worth $1,840,000 after purchasing an additional 709,677 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its holdings in shares of Vigil Neuroscience by 16.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company's stock worth $1,195,000 after purchasing an additional 97,580 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.